1. Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer
   Jieke Yan et al, 2017, Biomedicine & Pharmacotherapy CrossRef
2. Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix
   Asako Ueda et al, 2017, PLOS ONE CrossRef
3. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models
   Laura Muñoz-Moreno et al, 2014, Investigational New Drugs CrossRef
4. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer
   Masaki Shiota et al, 2015, Oncotarget CrossRef
5. Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
   Sushanta Halder et al, 2023, Expert Opinion on Therapeutic Targets CrossRef
6. Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach
   Asta Juzeniene et al, 2023, Frontiers in Medicine CrossRef
7. Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imaging
   Kenneth M Tichauer et al, 2014, Nature Medicine CrossRef
8. Improving target cell specificity using a novel monovalent bispecific IgG design
   Yariv Mazor et al, 2015, mAbs CrossRef
9. PLGA nanomedical consignation: A novel approach for the management of prostate cancer
   Tenzin Sonam Dongsar et al, 2024, International Journal of Pharmaceutics CrossRef
10. Expression of EGF receptors in canine prostate with proliferative inflammatory atrophy and carcinoma
    Mariana Batista Rodrigues Faleiro et al, 2017, Ciência Rural CrossRef
11. Targeted nanomedicine modalities for prostate cancer treatment
    Lital Cohen et al, 2021, Drug Resistance Updates CrossRef
12. Non-androgen Signaling Pathways in Castration-Resistant Prostate Cancer
    Sivanandane Sittadjody et al, 2016, Managing Metastatic Prostate Cancer In Your Urological Oncology Practice CrossRef
13. Determination of subcellular compartment sizes for estimating dose variations in radiotherapy
    Christopher M. Poole et al, 2015, Radiation Protection Dosimetry CrossRef
14. New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use
    Therese M. Becker et al, 2014, International Journal of Cancer CrossRef
15. Gemcitabine‐(5′‐phosphoramidate)‐[anti‐IGF‐1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)
    Cody P. Coyne et al, 2017, Chemical Biology & Drug Design CrossRef
16. Therapeutic Targeting of the Bone Pre-metastatic Niche
    Ester Simeone et al, 2013, Prostate Cancer: Shifting from Morphology to Biology CrossRef
17. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
    Yariv Mazor et al, 2017, Scientific Reports CrossRef
18. Cyclin D1 Serves as a Poor Prognostic Biomarker in Stage I Gastric Cancer
    Se-Il Go et al, 2022, Current Issues in Molecular Biology CrossRef